News Releases
Sep 27, 2022
Sept 27 – 29, 2022 Pharmasum Therapeutics presented at Nordic Life Science Days (NLSD)

Pharmasum Therapeutics presented at Nordic Life Science Days and met with investors and collaborators.

Jul 19, 2022
Pharmasum Therapeutics announces the publication of an article titled “DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes” in the journal Frontiers in Pharmacology.

The full article is available to download here:

May 25, 2022
Pharmasum Therapeutics has entered a collaboration agreement with the University of Oslo

The Company will perform studies in mouse models in collaboration with Professor Linda Hildegaard Bergersen at the University of Oslo. These studies will define the dose of the novel DYRK1A inhibitor development...

Feb 15, 2022
Pharmasum Therapeutics has received support from the highly competitive Regional Research Fund for the project “A novel drug for treating dementia in Down syndrome"

The Company has received support from the Regional Research Council to perform studies on mouse models of dementia.

Dec 16, 2021
Pharmasum Therapeutics presented at the annual DNB Healthcare Venture session

A link to the presentation is here: https://www.youtube.com/watch?v=Yhs5FpkszyQ

 

Nov 17, 2021
Pharmasum Therapeutics announces the publication of an article titled “Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome” in the journal Pharmaceuticals.

The full article is available to download here: https://www.mdpi.com/1424-8247/14/11/1170/htm

Nov 11, 2021
Pharmasum Therapeutics has been selected to present at the DNB healthcare conference December 16, 2021

The 12 most promising healthcare startups and scaleups will be presenting themselves to investors and potential partners at the DNB Healthcare Venture Session December 16, 2021. 

Nov 2, 2021
Pharmasum Therapeutics announces that the Company has moved into offices at the Oslo Science Park.

Pharmasum Therapeutics announces that the Company has moved into offices at the Oslo Science Park.

Oct 24, 2021
Pharmasum Therapeutics announces the nomination the DYRK1A protein kinase inhibitor PST-674 as the development candidate for dementia in Down syndrome.

The Board approved the selection of development candidate and back-up for further progression into scale-up and GLP tox/safety.

Feb 23, 2021
Pharmasum Therapeutics AS announces the granting and publishing of its US patent covering composition of matter claims

Pharmasum Therapeutics AS announces the granting and publishing of its US patent covering composition of matter claims, relating to the Company’s ongoing DYRK1A inhibitor program.

Jan 29, 2021
Pharmasum Therapeutics enters into the Euronext Share registry

At the Extraordinary General Assembly, Pharmasum Therapeutics AS declares that its shares shall be entered into the Euronext Share registry (formerly known as VPS).

Dec 14, 2020
Dr. Reijo Salonen and Dr. Anders Fugelli elected to the Board of Directors of Pharmasum Therapeutics

At the Annual General Assembly, Dr. Reijo Salonen, MD, PhD and Dr. Anders Fugelli, PhD were elected to the Board of Directors of Pharmasum Therapeutics. At the same time, the Company closed a significant funding...

Feb 24, 2019
Pharmasum was featured in the Norwegian Technical Weekly (Teknisk Ukeblad), talking about the ongoing dementia and cognition drug development program

An in-depth interview and corresponding Podcast are available (in Norwegian).

Click here to read article:

Dec 14, 2018
Pharmasum Therapeutics presented at DNB Healthcare conference, Venture Session

In Oslo, Norway

Jun 22, 2018
Pharmasum Therapeutics featured in the Norwegian Biotechnology Association publication

"Pharmasum is gearing up to enter clinical studies in Down syndrome.

We are trying to dramatically improve the lives of individuals with Down syndrome, by improving cognition and possibly slowing down...

May 23, 2018
Meet Pharmasum Therapeutics at the annual BIO meeting, Boston, USA

4th – 7th June 2018

Nov 13, 2017
Pharmasum participated in round-table discussions and gave a presentation at World HealthEx Forum and Inv€stival Showcase, in London, UK

13th - 14th November 2017

Sep 26, 2017
Pharmasum Therapeutics presented at Biotech Investment and Partnering meeting

In Basel, Switzerland.

Mar 26, 2017
Pharmasum Therapeutics presented at Annual Sachs Neuroscience meeting

At the NY Academy of Sciences, New York, USA.

Feb 10, 2017
Pharmasum Therapeutics successfully completes share issue

Pharmasum Therapeutics AS (“Pharmasum” or the “Company”), a neuroscience drug development company, is pleased to announce the successful completion of a share issue of NOK 8.3 million from...

Oct 18, 2016
Pharmasum receives 1.5 MNOK investment from Norwegian government fund
Sep 8, 2015
Norwegian Nobel Laureates receive 100 million NOK for neuroscience research
Jan 30, 2015
Pharmasum Therapeutics AS featured online NORD24
Jan 30, 2015
Pharmasum Therapeutics AS granted up to NOK 12 million from Norwegian Research Council to progress novel drugs for treatment of Alzheimer's disease

Tromsø, Norway, January 30, 2015 – Pharmasum Therapeutics AS (“Pharmasum” or the “Company”), a neuroscience drug development company, is pleased to announce the award of a grant...

Dec 10, 2014
Article in VG in connection with Nobel prize ceremony

Please click here to view PDF

Dec 1, 2014
Pharmasum featured in finance magazine Kapital

Please click here to view PDF

Oct 16, 2014
Pharmasum presented at memory symposium together with Nobel Laureate May-Brit Moser. Featured by Norwegian Broadcasting Association (NRK.no). Press button to read facsimile

Please click here to view PDF

Oct 7, 2014
A great day for Norwegian Neuroscience - 2014 Nobel Laureates in physiology or medicine announced. Article in Dagens Næringsliv

Please click here to view PDF

Oct 2, 2014
Pharmasum presented at EPIC Biotech conference in London
Apr 11, 2014
Pharmasum Theraputics presents at Anglo-Nordic Biotech meeting and featured twice in Norwegian finance news - Finansavisen

Please click here to view...